16,418 Shares of Illumina, Inc. $ILMN Bought by Ninety One North America Inc.

Ninety One North America Inc. bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 16,418 shares of the life sciences company’s stock, valued at approximately $4,493,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. BlackRock Inc. acquired a new stake in Illumina in the second quarter valued at approximately $3,374,423,000. Plato Investment Management Ltd bought a new stake in Illumina in the second quarter worth approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Illumina in the second quarter worth approximately $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in Illumina in the second quarter worth approximately $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Illumina during the 2nd quarter worth $6,711,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Illumina news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ILMN shares. Guggenheim raised their price target on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Barclays upped their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. Finally, Royal Bank Of Canada increased their target price on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $225.94.

Illumina Stock Performance

ILMN traded down $2.92 on Thursday, hitting $268.85. The company had a trading volume of 1,367,740 shares, compared to its average volume of 2,166,710. The company’s fifty day moving average price is $231.55 and its 200 day moving average price is $184.42. Illumina, Inc. has a 1-year low of $93.50 and a 1-year high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a market cap of $40.60 billion, a price-to-earnings ratio of 50.14, a price-to-earnings-growth ratio of 3.84 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.